Sugi Predict

Sugi Predict / Compounds / SCHEMBL4474965

SCHEMBL4474965

SCHEMBL4474965

NCCCCCCOC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 6/20 0.66
▸ MEN1 O00255 1/20 0.61
▸ ABL1 P00519 1/20 0.61
▸ LMNA P02545 1/20 0.61
▸ PKM P14618 1/20 0.61
▸ IDE P14735 1/20 0.61
▸ MAPK1 P28482 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ RIN1 Q13671 1/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ HLCS P50747 6/20 0.57
▸ HPSE Q9Y251 1/20 0.55
▸ CNR1 P21554 2/20 0.53
▸ CA12 O43570 3/20 0.48
▸ CA1 P00915 3/20 0.48
▸ CA2 P00918 3/20 0.48
▸ CA9 Q16790 3/20 0.48
▸ CNR2 P34972 1/20 0.47
▸ PLCD1 P51178 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10140322 0.92 TDP1 (0.70) TDP1MEN1ABL1LMNAPKM
SCHEMBL12186905 0.92 TDP1 (0.70) TDP1MEN1ABL1LMNAPKM
SCHEMBL19134287 0.91 CNR1 (0.65) TDP1MEN1ABL1LMNAPKM
SCHEMBL29046885 0.90 HLCS (0.73) TDP1MEN1ABL1LMNAPKM
SCHEMBL8392745 0.90 TDP1 (0.70) TDP1MEN1ABL1LMNAPKM
SCHEMBL7157942 0.90 TDP1 (0.77) TDP1MEN1ABL1LMNAPKM
SCHEMBL7902253 0.89 TDP1 (0.66) TDP1MEN1ABL1LMNAPKM
SCHEMBL10389671 0.89 HLCS (0.71) TDP1MEN1ABL1LMNAPKM
SCHEMBL7267179 0.89 HLCS (0.71) TDP1MEN1ABL1LMNAPKM
SCHEMBL2322596 0.89 HLCS (0.71) TDP1MEN1ABL1LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578450-A4 AMPLIFICATION OF BIOTIN-MEDIATED TARGETING ACCESS PHARMACEUTICALS AUSTRAL (AU) 2009-06-17 — — EP disclosed
US-20060127310-A1 Amplification of biotin-mediated targeting ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD. 2006-06-15 — — US disclosed
EP-1578450-A1 AMPLIFICATION OF BIOTIN-MEDIATED TARGETING Access Pharmaceuticals Australia Pty Ltd (AU) 2005-09-28 — — EP disclosed
WO-2004045647-A1 AMPLIFICATION OF BIOTIN-MEDIATED TARGETING ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD (AU) 2004-06-03 — — WO disclosed
EP-1030557-A4 PROTEIN DELIVERY BY SECRETORY GLAND EXPRESSION UNIV CALIFORNIA (US) 2002-07-31 — — EP disclosed
EP-1030557-A1 PROTEIN DELIVERY BY SECRETORY GLAND EXPRESSION The Regents of the University of California (US) 2000-08-30 — — EP disclosed
WO-1999017610-A1 PROTEIN DELIVERY BY SECRETORY GLAND EXPRESSION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060127310-A1 Amplification of biotin-mediated targeting BTD, HLCS, SLC1A5 TDP1 4434/4885MEN1 806/4885ABL1 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.